Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-937 Adjuvant Pembrolizumab in Hepatocellular Carcinoma
2022-501971-24-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Pembrolizumab with Placebo (2 arms). Primary endpoints: Recurrence-Free Survival and Overall Survival. Started May 2019; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2022-501971-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501971-24-00.